TCT Conference 2024 - Clinical outcomes between percutaneous mitral valve repair (PMVR) and mitral valve surgery in patients with atrial mitral regurgitation (MR).

Dr Stephan Baldus (University of Köln Medical Center, DE) joins us onsite at TCT Conference to discuss the findings from MATTERHORN (NCT02371512; University of Köln).

MATTERHORN is a multicenter, randomized controlled clinical trial, where high-surgical risk patients with advanced functional or ischemic mitral regurgitation and reduced left ventricular ejection fraction (LVEF ≥ 20%) were randomized to receive either the MitraClip system, or mitral valve surgical repair. 210 patients were enrolled in the study and were followed-up 12 months post intervention. The primary outcome measures were composite of death, rehospitalisation for heart failure, reintervention, assist device implantation and stroke within 12 months of surgery.

Findings showed that no subgroup-specific differences were found in the recurrence of MR between subgroups treated with the MitraClip system and subgroups who underwent mitral valve surgery; however, the MitraClip system demonstrated better safety outcomes than mitral valve surgery. Non-elevated event rates were found for the primary endpoints in all sub-groups for the MitrClip system and surgery.

Interview Questions:

1. What is the reasoning behind this trial? 
2. What are the current unmet needs in mitral regurgitation management?
3. Could you tell us about the patient population and study design for MATTERHORN?
4. What were the key findings?
5. Were there any surprising or unexpected results?
6. What further study is needed in this area?

Recorded at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.